Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES).

Jonathan BarrattBranislav AndricAvtandil TataradzeMichael SchömigMichael ReuschUdaya ValluriChristophe Mariat

Published in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2021)

Roxadustat is a viable option to treat anaemia in NDD CKD patients maintaining Hb levels for up to 104 weeks.

Keyphrases

end stage renal disease
chronic kidney disease
open label
newly diagnosed
peritoneal dialysis
ejection fraction
clinical trial
prognostic factors
randomized controlled trial
squamous cell carcinoma
double blind
radiation therapy
preterm birth
replacement therapy